Latest News & Features
Americas
Buyers of AbbVie’s arthritis treatment Humira have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit. 31 July 2020
Americas
The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more. 31 July 2020
Americas
Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission. 30 July 2020
Big Pharma
Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers. 30 July 2020
Americas
Counterfeit pills used to treat erectile dysfunction, heartburn and stomach ulcers have been discovered at Los Angeles International Airport (LAX), alongside fake luxury goods. 30 July 2020
Biotechnology
Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease. 30 July 2020
article
We are delighted to announce that Kelly Morgan, head of IP and legal at Arbor Biotechnologies, is to be interviewed as part of the LSPN Connect broadcast series on July 30 at 11am EDT/4pm BST. 30 July 2020
Biotechnology
The University of Texas is protected from being forced to become an involuntary plaintiff in an infringement suit because of sovereign immunity, the US Court of Appeals for the Federal Circuit ruled on Friday, July 24. 28 July 2020
Americas
A US federal appeals court has refused to block California’s ban on pay-for-delay deals in the generic drugs industry. 27 July 2020
Big Pharma
Biotech company Moderna has failed to have a US patent owned by its competitor Arbutus Biopharma revoked, following a decision handed down by the Patent Trial and Appeal Board (PTAB). 24 July 2020